Literature DB >> 7018813

Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients.

J A Millar, B P McGrath, P G Matthews, C I Johnston.   

Abstract

1. The acute effects of a single oral dose of captopril on blood pressure, pulse rate and circulating levels of angiotensin I (ANG I), angiotensin II (ANG II), renin, bradykinin and catecholamines were studied in three groups: eight normal subjects, six salt-depleted normal subjects and 16 patients with essential hypertension. 2. Captopril treatment did not cause any significant fall in supine blood pressure in salt-replete normal subjects or patients with untreated essential hypertension but was associated with a fall in mean blood pressure from 85 +/- 2 to 75 +/- 2 mmHg in salt-depleted normal subjects and from 131 +/- 7 to 117 +/- 5 mmHg in patients with essential hypertension treated with diuretics. There was no change in pulse rate in any group. 3. Hormonal responses to captopril were qualitatively similar in the three groups and consisted of significant falls in ANG II with corresponding increases in ANG I and plasma renin concentration. The changes in plasma renin concentration and ANG I were greater in salt-depleted normal subjects (mean values at 90 min were 1140% and 990% of basal levels respectively) than in salt-replete normal subjects (410%, 190%) and were blunted in patients with essential hypertension (140%, 120%). Blood bradykinin, noradrenaline and adrenaline concentrations did not change after captopril in any group. 4. The parallel fall in blood pressure and ANG II levels in salt-depleted normal subjects is consistent with maintenance of blood pressure by increased levels of ANG II in sodium depletion. 5. The failure of captopril to reduce acutely blood pressure in patients with essential hypertension despite suppression of plasma ANG II and without change in circulating bradykinin confirms that the renin-angiotensin system does not play a primary role in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018813     DOI: 10.1042/cs0610075

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

Review 1.  Is salt restriction relevant and feasible as adjunctive treatment of hypertension?

Authors:  M H Weinberger
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside.

Authors:  R H Becker; A D Struthers; M J Brown
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

3.  The influence of naloxone on the circulatory effects of captopril.

Authors:  P C Rubin; J A Millar; S Sturani; C Lawrie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

4.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

5.  Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

Authors:  C I Johnston; B J Jackson; I Larmour; R Cubella; D Casley
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Sodium and water balance in chronic congestive heart failure.

Authors:  R J Cody; A B Covit; G L Schaer; J H Laragh; J E Sealey; J Feldschuh
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

7.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.